Search research articles
Contact Us
Filters
Showing results (101-110 of 121) with videos related to
Page
of 13
Sort By:
Annals of Hematology
|
December 10, 2025
Predicting the toxicity-efficacy ratio of venetoclax in real-world patients
Loïc Osanno, Lucy Brocque, Laurent Bourguignon, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
May 22, 2026
External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV-Infected Patients
Quentin Renou, Nadège Néant, Alexandre Destere, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 18, 2025
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With Human Immunodeficiency Virus Type 1: First Results From the ANRS-MIE CARLAPOP Study
Nadège Néant, Minh P Lê, Stéphane Bouchet, et al.
British Journal of Clinical Pharmacology
|
October 28, 2021
Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low-grade glioma
Mourad Hamimed, Florence Gattacceca, Nicolas André, et al.
Open Forum Infectious Diseases
|
July 30, 2025
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions
Anna Maria Geretti, Marta Boffito, Stefano Bonora, et al.
Antiviral Research
|
April 5, 2026
Preclinical efficacy of a Favipiravir and Nitazoxanide Combination Against Rift Valley Fever Virus
Sarah Chaput, Jean-Sélim Driouich, Boris Pastorino, et al.
European Journal of Gastroenterology & Hepatology
|
December 19, 2019
Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit
Caroline Lions, Helene Laroche, Olivia Zaegel-Faucher, et al.
Heliyon
|
May 28, 2024
Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns
Paul-Rémi Petit, Franck Touret, Jean-Sélim Driouich, et al.
Journal of Medical Virology
|
July 24, 2014
Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France
Sarah Aherfi, Caroline Solas, Anne Motte, et al.
Cancer Chemotherapy and Pharmacology
|
June 25, 2022
Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis
Mourad Hamimed, Pierre Leblond, Aurélie Dumont, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 121) with videos related to
Sort By:
Page
of 13
Annals of Hematology
|
December 10, 2025
Predicting the toxicity-efficacy ratio of venetoclax in real-world patients
Loïc Osanno, Lucy Brocque, Laurent Bourguignon, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
May 22, 2026
External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV-Infected Patients
Quentin Renou, Nadège Néant, Alexandre Destere, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 18, 2025
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With Human Immunodeficiency Virus Type 1: First Results From the ANRS-MIE CARLAPOP Study
Nadège Néant, Minh P Lê, Stéphane Bouchet, et al.
British Journal of Clinical Pharmacology
|
October 28, 2021
Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low-grade glioma
Mourad Hamimed, Florence Gattacceca, Nicolas André, et al.
Open Forum Infectious Diseases
|
July 30, 2025
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions
Anna Maria Geretti, Marta Boffito, Stefano Bonora, et al.
Antiviral Research
|
April 5, 2026
Preclinical efficacy of a Favipiravir and Nitazoxanide Combination Against Rift Valley Fever Virus
Sarah Chaput, Jean-Sélim Driouich, Boris Pastorino, et al.
European Journal of Gastroenterology & Hepatology
|
December 19, 2019
Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit
Caroline Lions, Helene Laroche, Olivia Zaegel-Faucher, et al.
Heliyon
|
May 28, 2024
Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns
Paul-Rémi Petit, Franck Touret, Jean-Sélim Driouich, et al.
Journal of Medical Virology
|
July 24, 2014
Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France
Sarah Aherfi, Caroline Solas, Anne Motte, et al.
Cancer Chemotherapy and Pharmacology
|
June 25, 2022
Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis
Mourad Hamimed, Pierre Leblond, Aurélie Dumont, et al.
Page
of 13